Coherus Biosciences Inc (NASDAQ:CHRS) price on current trading day, rose 2.23% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.91.
A look at the stock’s price movement, the close in the last trading session was $0.89, moving within a range at $0.889 and $0.95. The beta value (5-Year monthly) was 0.925 while the PE ratio in trailing twelve months stood at 5.20. Turning to its 52-week performance, $2.64 and $0.66 were the 52-week high and 52-week low respectively. Overall, CHRS moved -18.99% over the past month.
Coherus Biosciences Inc’s market cap currently stands at around $105.14 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-09.
Analysts have a consensus estimate of 59.79M for the company’s revenue for the quarter, with a low and high estimate of 52.36M and 72M respectively. The average forecast suggests down to a -22.42% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 103.15M, representing a -61.36% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CHRS is a 100% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 3 recommend CHRS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CHRS’s current price about -11.49% and -22.72% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 36.41, while 7-day volatility ratio is 9.30% and 9.38% in the 30-day chart. Further, Coherus Biosciences Inc (CHRS) has a beta value of 0.97, and an average true range (ATR) of 0.10. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -559.34% off current price level while to achieve the yearly target high, price needs to move -559.34%. Nonetheless, investors will most likely welcome a -559.34% jump to $6 which is the analysts’ median price.
If we refocus on Coherus Biosciences Inc (NASDAQ:CHRS), historical trading data shows that trading volumes averaged 2.26 over the past 10 days and 2.01 million over the past 3 months. The company’s latest data on shares outstanding shows there are 115.89 million shares.
The 3.97% of Coherus Biosciences Inc’s shares are in the hands of company insiders while institutional holders own 54.15% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 30.77 million on 2025-02-28, giving us a short ratio of 18.43. The data shows that as of 2025-02-28 short interest in Coherus Biosciences Inc (CHRS) stood at 3096.9997999999996 of shares outstanding, with shares short falling to 30.9 million registered in 2025-01-31. Current price change has pushed the stock -34.25% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CHRS stock continues to rise going into the next quarter.
